Jiangsu Sinopep-Allsino Biopharmaceutical Future Growth
Future criteria checks 6/6
Jiangsu Sinopep-Allsino Biopharmaceutical is forecast to grow earnings and revenue by 31.4% and 31.5% per annum respectively. EPS is expected to grow by 32.2% per annum. Return on equity is forecast to be 23.1% in 3 years.
Key information
31.4%
Earnings growth rate
32.2%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 31.5% |
| Future return on equity | 23.1% |
| Analyst coverage | Low |
| Last updated | 31 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?
Sep 26
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable
Jun 23Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 04There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump
Mar 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,184 | 820 | 670 | 701 | 5 |
| 12/31/2025 | 2,382 | 601 | -154 | 493 | 5 |
| 12/31/2024 | 1,774 | 439 | -373 | 327 | 5 |
| 9/30/2024 | 1,576 | 421 | -495 | 382 | N/A |
| 6/30/2024 | 1,464 | 348 | -365 | 376 | N/A |
| 3/31/2024 | 1,181 | 208 | -445 | 284 | N/A |
| 12/31/2023 | 1,034 | 163 | -310 | 350 | N/A |
| 9/30/2023 | 979 | 168 | -271 | 280 | N/A |
| 6/30/2023 | 784 | 136 | -244 | 217 | N/A |
| 3/31/2023 | 725 | 134 | -218 | 173 | N/A |
| 12/31/2022 | 651 | 129 | -409 | 29 | N/A |
| 9/30/2022 | 576 | 95 | -349 | 33 | N/A |
| 6/30/2022 | 603 | 99 | -307 | 80 | N/A |
| 3/31/2022 | 612 | 92 | -169 | 168 | N/A |
| 12/31/2021 | 644 | 115 | -53 | 181 | N/A |
| 9/30/2021 | 642 | 113 | -34 | 173 | N/A |
| 6/30/2021 | 660 | 126 | 116 | 245 | N/A |
| 3/31/2021 | 687 | 159 | 54 | 165 | N/A |
| 12/31/2020 | 567 | 123 | 30 | 141 | N/A |
| 9/30/2020 | 481 | 94 | -24 | 104 | N/A |
| 6/30/2020 | 425 | 74 | -131 | 65 | N/A |
| 3/31/2020 | 353 | 46 | -177 | 66 | N/A |
| 12/31/2019 | 372 | 49 | -230 | 46 | N/A |
| 9/30/2019 | 313 | 40 | -220 | 90 | N/A |
| 6/30/2019 | 266 | 31 | -205 | 62 | N/A |
| 3/31/2019 | 298 | 59 | -198 | 43 | N/A |
| 12/31/2018 | 256 | 44 | -101 | 96 | N/A |
| 9/30/2018 | 284 | 66 | -137 | 23 | N/A |
| 6/30/2018 | 286 | 71 | N/A | -43 | N/A |
| 3/31/2018 | 245 | 46 | N/A | 40 | N/A |
| 12/31/2017 | 229 | 42 | N/A | 11 | N/A |
| 9/30/2017 | 156 | -7 | N/A | 51 | N/A |
| 6/30/2017 | 104 | -46 | N/A | 78 | N/A |
| 3/31/2017 | 26 | -66 | N/A | -4 | N/A |
| 12/31/2016 | 9 | -75 | N/A | -22 | N/A |
| 9/30/2016 | 6 | -53 | N/A | -79 | N/A |
| 6/30/2016 | 3 | -33 | N/A | -137 | N/A |
| 3/31/2016 | 6 | -32 | N/A | -125 | N/A |
| 12/31/2015 | 9 | -30 | N/A | -113 | N/A |
| 12/31/2014 | N/A | -25 | N/A | 68 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688076's forecast earnings growth (31.4% per year) is above the savings rate (2.8%).
Earnings vs Market: 688076's earnings (31.4% per year) are forecast to grow faster than the CN market (26.2% per year).
High Growth Earnings: 688076's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688076's revenue (31.5% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 688076's revenue (31.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688076's Return on Equity is forecast to be high in 3 years time (23.1%)